10-Q: Movano Health Faces Liquidity Crisis, Nasdaq Threat

Movano Inc. reported reduced Q2 losses but confronts substantial doubt about its going concern ability and Nasdaq delisting, prompting a bridge loan and strategic review.

Summary

• Movano Inc. reported a net loss of $3.2 million for the three months ended June 30, 2025, an improvement from a $6.2 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $8.4 million, compared to $11.9 million for the six months ended June 30, 2024.
• Revenue for the three months ended June 30, 2025, was $0.1 million, up from $0 in the prior year, while six-month revenue decreased to $0.3 million from $0.9 million.
• Cash and cash equivalents significantly declined to $2.1 million as of June 30, 2025, from $7.9 million at December 31, 2024.
• The company used $7.4 million in cash from operating activities during the first six months of 2025.
• Movano has an accumulated deficit of $156.5 million as of June 30, 2025, and expects its current cash to not be sufficient to fund operations beyond 2025, raising substantial doubt about its ability to continue as a going concern.
• The Board of Directors initiated a process on May 15, 2025, to explore strategic alternatives to maximize shareholder value, engaging Aquilo Partners and K&L Gates LLP.
• Movano obtained $1.5 million in bridge financing on August 6, 2025, bearing 12.0% interest and maturing on November 4, 2025, with a security interest granted in all company assets, including intellectual property.
• The company received FDA 510(k) clearance for the pulse oximetry feature in its EvieMED Ring in November 2024, positioning it as a medical device for prescription sales.
• Movano is developing a System-on-a-Chip (SoC) for non-invasive continuous glucose monitoring (CGM) and cuffless blood pressure monitoring, currently undergoing clinical trials.
• The company faced Nasdaq non-compliance issues for both minimum bid price and delayed 10-Q filings, but has been granted continued listing conditional on regaining compliance by specific deadlines in September and October 2025.
• Material weaknesses in internal controls over financial reporting were identified as of December 31, 2024, and disclosure controls were not effective as of June 30, 2025.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including substantial doubt about its ability to continue as a going concern, critically low cash reserves, and ongoing Nasdaq delisting threats. While there's progress in product development and reduced quarterly losses, the immediate liquidity and operational risks are paramount, indicating a highly precarious situation.

Positives

• Net loss significantly decreased by 48% to $3.2 million for the three months ended June 30, 2025, compared to $6.2 million in the prior year period.
• Operating expenses were substantially reduced across all categories for both the three and six-month periods, including a 52% decrease in Research and Development expenses for the quarter.
• Received FDA 510(k) clearance for the pulse oximetry feature in the EvieMED Ring in November 2024, enabling its sale as a medical device via prescription.
• Progress in developing a proprietary System-on-a-Chip (SoC) for non-invasive continuous glucose monitoring and cuffless blood pressure monitoring, with clinical trials underway.
• Successfully filed the delayed Quarterly Reports on Form 10-Q for Q1 and Q2 2025 by the Nasdaq deadline of September 30, 2025.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern beyond 2025 due to significant losses and insufficient cash reserves.
• Cash and cash equivalents decreased by 73% to $2.1 million at June 30, 2025, from $7.9 million at December 31, 2024.
• Revenue for the six months ended June 30, 2025, decreased by 64% to $0.3 million from $0.9 million in the prior year period, primarily due to reduced marketing efforts.
• The company incurred a high-interest bridge loan of $1.5 million at 12.0% per annum, secured by all company assets, including intellectual property, with a potential loan premium of double the outstanding principal upon certain triggering events.
• Movano faces a Nasdaq delisting threat for failing to maintain a $1.00 bid price, with a deadline of October 30, 2025, to regain compliance, and is considering another reverse stock split.
• Material weaknesses in internal controls over financial reporting were identified as of December 31, 2024, and disclosure controls were deemed ineffective as of June 30, 2025.
• The at-the-market (ATM) issuance program, which provided $1.6 million in net proceeds during the first half of 2025, was terminated in May 2025 upon the expiration of the company's Registration Statement on Form S-3.

Risks

• Inability to continue as a going concern if additional capital is not successfully raised on favorable terms or if sufficient revenue is not generated from operations.
• Failure to meet Nasdaq's continued listing requirements, specifically the $1.00 minimum bid price by October 30, 2025, which could lead to delisting.
• Significant dilution for existing stockholders if additional funds are raised through equity or convertible debt securities.
• Restrictive covenants and increased expenses associated with potential debt financing, and the lack of significant assets for collateral.
• Dependence on third-party manufacturers and potential adverse effects from supply interruptions.
• Uncertainty regarding the feasibility and successful development and commercialization of products, including the Evie Ring, EvieMED Ring, and SoC.
• Impact of competitive or alternative products, technologies, and pricing in the health tech market.
• Inability to attract and retain highly qualified personnel and dependence on consultants for technology development.
• Risks associated with protecting intellectual property, including patents, and potential claims of infringement.
• Need to secure required FCC, FDA, and other regulatory approvals for products.
• Material weaknesses in internal controls over financial reporting and ineffective disclosure controls and procedures.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future as it develops its technology and commercializes products. It anticipates requiring additional financing to fund future planned operations, including research and development and commercialization of products, and will likely raise capital through equity issuance, borrowings, or strategic alliances. The ultimate goal is to bring a Class II FDA-cleared device to market with non-invasive continuous glucose monitoring and cuffless blood pressure capabilities. The Board is actively exploring strategic alternatives to maximize shareholder value.

Management Comments

• Management believes that cash and cash equivalents as of June 30, 2025, will not be sufficient to fund projected operating requirements beyond 2025.
• Management anticipates incurring additional losses until such time, if ever, that significant sales can be generated.
• Management will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies.

Industry Context

Movano Health operates in the highly competitive and rapidly evolving wearable health technology and medical device industry. Its Evie Ring targets the general wellness market, while the FDA-cleared EvieMED Ring aims for clinical applications like remote patient monitoring, differentiating itself by having FDA clearance on the entire system (hardware and software). The development of a System-on-a-Chip for non-invasive continuous glucose monitoring and cuffless blood pressure positions Movano in a high-growth, high-potential segment, seeking to address significant unmet needs in chronic disease management, where current solutions often involve more invasive or cumbersome methods.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Management is not currently aware of any pending legal proceedings that are believed to have a material adverse impact on the company's business or financial condition.

Related Party Transactions

• The company enters into standard indemnification agreements in the ordinary course of business with its directors and officers, which may require indemnification against liabilities arising from their service, excluding willful misconduct.

Stakeholder Impact

• Shareholders face significant risk of dilution from future capital raises and potential loss of investment due to the substantial doubt about the company's ability to continue as a going concern.
• Shareholders are exposed to the risk of Nasdaq delisting, which could negatively impact stock price and liquidity.
• Employees and directors received Restricted Stock Units (RSUs) in lieu of salary and cash compensation, indicating financial strain and potential impact on employee morale and retention.
• Creditors, particularly the lender of the bridge loan, have a security interest in all company assets, including intellectual property, indicating a high-risk lending scenario.

Next Steps

• Regain compliance with Nasdaq's $1.00 minimum bid price requirement on or before October 30, 2025, potentially through a reverse stock split to be approved at the Annual Shareholders Meeting on September 26, 2025.
• Continue the process of exploring strategic alternatives to maximize shareholder value.
• Secure additional financing through equity offerings, debt financings, or strategic alliances to fund operations beyond 2025.
• Continue clinical trials and development of the System-on-a-Chip for non-invasive continuous glucose monitoring and cuffless blood pressure capabilities.
• Address and remediate the identified material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

Movano Inc. is in a critical financial state, facing substantial doubt about its ability to continue as a going concern beyond 2025 due to critically low cash reserves and ongoing significant losses. The company has resorted to high-interest, asset-collateralized bridge financing and is actively exploring strategic alternatives, which often precede distressed asset sales or bankruptcy. Persistent Nasdaq delisting threats, despite recent compliance efforts, further underscore the severe operational and financial instability. While product development shows promise, the immediate and overwhelming liquidity and solvency risks make the stock a highly speculative and dangerous investment.

Keywords

Movano Health, Evie Ring, EvieMED Ring, FDA clearance, wearable technology, health monitoring, non-invasive glucose monitoring, cuffless blood pressure, SEC filing, 10-Q, financial results, Nasdaq listing, going concern, capital raise, strategic alternatives, medical device, System-on-a-Chip